Jump to any asset
849 assets, updated daily
As of September 27, 2026, MetLife, Inc. (MET) trades at $97.70. CleaRank Financial AI rates it Buy with a fair value of $108.00, 10.5% above the current price. Wall Street's consensus target is $108.00 across 18 analysts. RSI at 50 is in neutral territory, and the price is above its 50-day average of $96.28.
MetLife, Inc. (MET)
MetLife, Inc. NYSE
$97.70
0.4500 (0.46%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
72 / 100
MetLife, Inc. (MET) is currently trading at $97.70, above its 50-day and 200-day moving averages ($96.28 and $83.40), indicating positive short-to-medium term momentum. The company's consensus rating is Buy, supported by a Wall Street score of 72 and a median analyst price target of $108.00, suggesting an upside of 10.5%. Recent earnings have shown consistent beats, with the latest quarter to June 2026 exceeding estimates by 6.11% and driving a 3.83% stock price increase. Forward estimates point to continued revenue growth and EPS expansion, positioning the company favorably within the Financial Services sector. Valuation metrics show MetLife trading at a P/E ratio of 18.72, slightly above the sector median of 16.5, and a price-to-sales ratio of 0.78, which is below the sector median of 3.8. The company's return on equity stands at 13.09%, aligning with the sector average of 13.8%. While insider sentiment is moderately bearish with net selling activity totaling $3.8 million, this is largely attributed to corporate restructuring rather than a lack of confidence in the business. The company also offers a dividend yield of approximately 2.38%.
MET Price Analysis
Market Metrics
Open
$97.54
Day Range
$96.67 to $98.45
Prev Close
$97.25
Volume
3.63M
52-Week Range
$67.33 to $100.93
Market Cap
$62.09B
Peer Benchmarking
Valuation vs Sector (Financial Services)
Performance vs KIE
Sector Position Analysis
Valuation is broadly in line with sector peers (13% difference), suggesting fair market pricing relative to industry standards.
MET Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, MET beat estimates 4 times. However, the stock fell 2 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
MET Analysis
Company's Health
4/5
12-Month Analyst Target
+10.54% Upside
Median of 18 analysts (12-month)
$108.00
AI Technical Analysis
MetLife, Inc. (MET) exhibits neutral momentum with its Relative Strength Index (RSI) at 50.44, indicating neither overbought nor oversold conditions. The stock is trading above its 50-day and 200-day moving averages ($96.28 and $83.40), as well as its 20-day exponential moving average ($96.84), suggesting an overall upward trend. The Moving Average Convergence Divergence (MACD) is currently positive at 0.41, reinforcing the bullish short-term trend. Key support levels are found near the 50-day SMA at $96.28, with resistance potentially emerging around the $100 mark and the upper end of the analyst target range. Trading volume has been slightly above its average, with the latest volume at 3.63 million compared to an average of 3.33 million, indicating healthy investor interest. The current chart structure suggests continued stability with potential for upward movement if key resistance levels are breached.
ProTips
- Monitor the projected revenue decline in the next quarter for any signs of further weakness or stabilization.
- MetLife's dividend yield of approximately 2.38% may appeal to income-focused investors, but consider the moderate insider selling signal.
- As a large-cap insurer, MetLife's performance is sensitive to interest rate movements and regulatory environments. Stay informed on macroeconomic trends and policy changes.
Key Catalysts
Bullish
Consistent Earnings Beats
MetLife has a strong track record of exceeding EPS estimates, with the latest quarter to June 2026 showing a 6.11% beat, driving positive stock performance.
Source: Earnings ReportsBullish
Positive Forward Growth Estimates
Analysts project strong EPS growth of 11.97% for the current year and 10.6% for the next year, indicating strong future earnings potential.
Source: Wall Street EstimatesBullish
Above Key Moving Averages
The stock is trading above its 50-day and 200-day moving averages ($96.28 and $83.40), indicating positive technical momentum and potential for further price appreciation.
Source: Technical AnalysisBearish
Moderate Insider Selling
Insiders have sold $3.8 million worth of stock, signaling a moderate sell-off, although attributed to corporate restructuring.
Source: Insider TransactionsBearish
Projected Next Quarter Revenue Decline
Revenue is estimated to decrease by 15.00% year-over-year in the next quarter, potentially indicating short-term headwinds.
Source: Wall Street EstimatesMarket Outlook
MetLife, Inc. (MET) is expected to maintain its positive trajectory, with analysts projecting current year EPS growth of 11.97% and next year growth of 10.6%. The median price target of $108.00 suggests a potential upside of 10.5% from the current price of $97.70, supported by a strong Buy consensus from 18 analysts. The company's consistent earnings beats and above-average revenue growth estimates for the current year provide a solid foundation for this outlook. Key catalysts for upside include continued strong performance in its insurance and annuity segments, potential for further margin expansion, and favorable interest rate environments. Downside risks include a projected revenue decline of 15.00% in the next quarter, increased competition, and potential regulatory changes within the financial services sector. Insider selling, though moderate and attributed to restructuring, warrants monitoring.
Key Statistics
| Market Cap | 62.09B |
|---|---|
| P/E Ratio | 18.72 |
| EPS (TTM) | 5.22 |
| Dividend Yield | 2.38% |
| 52 Week High | 100.93 |
| 52 Week Low | 67.33 |
MetLife, Inc. (MET) presents a mixed valuation picture, trading at a P/E ratio of 18.72, which is above the Financial Services sector median of 16.5, but its price-to-sales ratio of 0.78 is well below the sector median of 3.8. The company's return on equity (ROE) of 13.09% is closely aligned with the sector average of 13.8%, indicating comparable profitability efficiency. Growth prospects appear solid, with projected current year revenue growth of 1.00% and next year growth of 5.00%, alongside an estimated current year EPS growth of 11.97%. The company's profit margin of 4.57% and operating margin of 5.52% are respectable within its industry. However, its debt-to-equity ratio of 1.80 is higher than the sector average of 1.8, suggesting a more leveraged balance sheet. Despite this, the consistent earnings beats and positive forward estimates provide a foundation for its current valuation.
Earnings & Growth Analysis
MetLife, Inc. (MET) has demonstrated a consistent pattern of exceeding analyst expectations in its recent quarterly earnings reports. The most recent quarter to June 2026 saw actual EPS of $2.43, surpassing the estimate of $2.29 by 6.11% and leading to a 3.83% increase in stock price. Prior quarters also show positive surprises, including a 9.74% beat in the quarter to June 2026 (reported July 27) and a 6.61% beat in the quarter to March 2026. This track record of earnings performance suggests strong operational execution and effective financial management.
Key Risks
MetLife, Inc. (MET) faces moderate risks stemming from its insider sentiment, which shows a net selling signal with $3.8 million in sales, although this is attributed to corporate restructuring. The company's debt-to-equity ratio of 1.80 is higher than the sector average, indicating increased financial leverage. Additionally, while revenue growth is positive, the projected -15.00% year-over-year change for the next quarter could signal short-term headwinds or seasonality within the insurance industry.
Technical Indicators
| RSI (14) | 50.44 |
|---|---|
| MACD | 0.41 |
| SMA 50 | 96.28 |
| SMA 200 | 83.40 |
RSI
Neutral
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($96.28) above the 200-day SMA ($83.40), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.61
Moderate correlation
Nasdaq 100 (QQQ)
+0.45
Moderate correlation
Bitcoin (BTC)
+0.24
Weak correlation
Gold (XAU)
+0.00
Weak correlation
Check Custom Correlation
How does any other asset move with MET? One year of daily closes, Pearson correlation.
Try
MET Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$95.75
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$97.70
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$92.87
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (50.4) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$100.53
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$105.32
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$110.11
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for MET is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 27, 2026.Growth of $10,000
A $10,000 investment in MET in September 2016 would be worth about $25,056 today, compared with about $35,782 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MET today could grow to about $22,462 by 2036 in the base case, with a bull case near $76,029 and a bear case around $6,636. Projections are statistical simulations, not guarantees.
MET Stock Price Prediction: 2030
CleaRank's simulation projects a price near $135 for MET by 2030 in the base case, from $97.70 today (1.4x over 4 years). The downside path ends near $62.46. These are outcomes of a Monte Carlo simulation run on MET's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $72.04 | $106 | $156 |
| 2028 | $66.58 | $115 | $198 |
| 2029 | $63.87 | $125 | $243 |
| 2030 | $62.46 | $135 | $292 |
| 2031 | $61.83 | $146 | $347 |
| 2032 | $61.74 | $159 | $408 |
| 2033 | $62.07 | $172 | $477 |
| 2034 | $62.72 | $187 | $555 |
| 2035 | $63.66 | $202 | $644 |
| 2036 | $64.84 | $219 | $743 |
Method: 10,000 simulated price paths using MET's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
MET Insider Trading Analysis
Bought
None
No open-market buys
Sold
$3.8M
2 Transactions
Insiders
23
Active Traders
Avg Transaction
$1.9M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Dec 12, 2022 | KHALAF MICHEL
Chief Executive Officer
|
Sell | 57.2K | $4.1M |
| Feb 8, 2022 | GOULART STEVEN J
Chief Investment Officer
|
Sell | 56.9K | $4.0M |
| Dec 21, 2021 | KHALAF MICHEL
Chief Executive Officer
|
Sell | 42.7K | $2.6M |
| Dec 12, 2022 | GOULART STEVEN J
Chief Investment Officer
|
Sell | 29.4K | $2.1M |
| May 12, 2025 | PAPPAS BILL
Officer
|
Sell | 26.0K | $2.1M |
| Mar 18, 2024 | PAPPAS BILL
Officer
|
Sell | 27.0K | $2.0M |
| Dec 13, 2024 | DEBEL MARLENE
Officer
|
Sell | 22.8K | $1.9M |
| Jun 1, 2026 | DEBEL MARLENE
Officer
|
Sell | 21.3K | $1.7M |
| Dec 13, 2024 | KHALAF MICHEL
Chief Executive Officer
|
Sell | 20.9K | $1.7M |
| Feb 5, 2024 | KHALAF MICHEL
Chief Executive Officer
|
Sell | 20.5K | $1.3M |
Page 1 of 1
Frequently Asked Questions
What is MetLife's stock forecast for 2030?
MetLife's stock forecast for 2030, based on Monte Carlo simulations, projects a base case price of $135.04, with a downside scenario at $62.46 and an upside scenario at $292. These are statistical outcomes, not guarantees.
Is MetLife, Inc. stock a buy right now?
MetLife, Inc. (MET) is currently rated as a Buy by Wall Street analysts, with a median price target of $108.00, suggesting a 10.5% upside from its current price of $97.70. The stock is trading above key moving averages and has a history of earnings beats.
What are the key technical indicators for MetLife stock?
MetLife's RSI is neutral at 50.44, and it is trading above its 50-day and 200-day moving averages ($96.28 and $83.40), indicating positive momentum. The MACD is also positive, reinforcing a bullish short-term trend.
How does MetLife's financial health compare to its peers?
MetLife's ROE of 13.09% is in line with the sector average of 13.8%, but its debt-to-equity ratio of 1.80 is slightly higher than the sector median. Its P/E ratio of 18.72 is above the sector median, while its P/S ratio of 0.78 is below.
What is the recent insider trading activity for MetLife?
Insider activity for MetLife shows a moderate sell signal, with $29.8M in total sales versus $0 in total purchases in recent filings. This is attributed to corporate restructuring rather than a lack of confidence.
What are the growth prospects for MetLife?
MetLife is projected to achieve current year EPS growth of 11.97% and next year EPS growth of 10.6%. Revenue growth is estimated at 1.00% for the current year and 5.00% for the next year.
What is MetLife's dividend yield?
MetLife, Inc. offers a dividend yield of approximately 2.38%, with a dividend rate of $2.32.